158 related articles for article (PubMed ID: 24650640)
41. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
42. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors.
Bhuva HA; Kini SG
J Mol Graph Model; 2010 Aug; 29(1):32-7. PubMed ID: 20493747
[TBL] [Abstract][Full Text] [Related]
43. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
[TBL] [Abstract][Full Text] [Related]
44. Rapid access to α-carbolines via a one-pot tandem reaction of α,β-unsaturated ketones with 2-nitrophenylacetonitrile and the anti-proliferative activities of the products.
Zhang X; He Q; Xiang H; Song S; Miao Z; Yang C
Org Biomol Chem; 2014 Jan; 12(2):355-61. PubMed ID: 24263172
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.
Li S; Guo C; Zhao H; Tang Y; Lan M
Bioorg Med Chem; 2012 Jan; 20(2):877-85. PubMed ID: 22182581
[TBL] [Abstract][Full Text] [Related]
46. Discovery of a selective irreversible BMX inhibitor for prostate cancer.
Liu F; Zhang X; Weisberg E; Chen S; Hur W; Wu H; Zhao Z; Wang W; Mao M; Cai C; Simon NI; Sanda T; Wang J; Look AT; Griffin JD; Balk SP; Liu Q; Gray NS
ACS Chem Biol; 2013 Jul; 8(7):1423-8. PubMed ID: 23594111
[TBL] [Abstract][Full Text] [Related]
47. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and in vitro and in vivo antitumor activities of novel beta-carboline derivatives.
Cao R; Chen H; Peng W; Ma Y; Hou X; Guan H; Liu X; Xu A
Eur J Med Chem; 2005 Oct; 40(10):991-1001. PubMed ID: 15950325
[TBL] [Abstract][Full Text] [Related]
50. Design of beta-carboline derivatives as DNA-targeting antitumor agents.
Guan H; Chen H; Peng W; Ma Y; Cao R; Liu X; Xu A
Eur J Med Chem; 2006 Oct; 41(10):1167-79. PubMed ID: 16790297
[TBL] [Abstract][Full Text] [Related]
51. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
52. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and quantitative structure-activity relationship of cytotoxic gamma-carboline derivatives.
Chen J; Dong X; Liu T; Lou J; Jiang C; Huang W; He Q; Yang B; Hu Y
Bioorg Med Chem; 2009 May; 17(9):3324-31. PubMed ID: 19359185
[TBL] [Abstract][Full Text] [Related]
54. Novel trisubstituted harmine derivatives with original in vitro anticancer activity.
Frédérick R; Bruyère C; Vancraeynest C; Reniers J; Meinguet C; Pochet L; Backlund A; Masereel B; Kiss R; Wouters J
J Med Chem; 2012 Jul; 55(14):6489-501. PubMed ID: 22770529
[TBL] [Abstract][Full Text] [Related]
55. [Synthesis and biological evaluation of tetrahydro-beta-carline derivatives].
Ruan XQ; You QD; Yang L; Wu WT
Yao Xue Xue Bao; 2008 Aug; 43(8):828-32. PubMed ID: 18956775
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and biological evaluation of 1,9-disubstituted β-carbolines as potent DNA intercalating and cytotoxic agents.
Chen Z; Cao R; Shi B; Guo L; Sun J; Ma Q; Fan W; Song H
Eur J Med Chem; 2011 Oct; 46(10):5127-37. PubMed ID: 21875764
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
58. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.
Abou-Seri SM
Eur J Med Chem; 2010 Sep; 45(9):4113-21. PubMed ID: 20580136
[TBL] [Abstract][Full Text] [Related]
60. Bruton's tyrosine kinase as a drug discovery target.
Pan Z
Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
